Target intelligence / Profile preview

Haemophilus influenzae type b polyribosyl-ribitol-phosphate polysaccharide–tetanus toxoid conjugate (PRP-T)

Target: PRP-T
Molecular classification: Other (Bacterial polysaccharide-antigen conjugate)

Overview

Haemophilus influenzae type b polyribosyl-ribitol-phosphate polysaccharide–tetanus toxoid conjugate is a component of Hib vaccines such as Hiberix and ActHIB. It consists of a purified capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP) from Haemophilus influenzae type b, covalently linked to tetanus toxoid, which acts as a carrier protein. This conjugate is formulated as a lyophilized powder for reconstitution and intramuscular injection. Its purpose is to induce a strong immune response in infants and young children, protecting them from invasive Hib diseases by generating IgG antibodies against the bacterial capsule. This conjugate is not a molecular target for drugs but rather a synthetic antigen used to stimulate protective immunity. Its clinical role is exclusively preventive (immunization).

Other names: Haemophilus influenzae type b conjugate (tetanus toxoid conjugate)PRP-T conjugateHiberix antigen componentHib capsular polysaccharide–tetanus conjugateHaemophilus b capsular polysaccharide–tetanus toxoid conjugate

Mechanism of action

Induces generation of specific antibodies against the PRP capsule of Haemophilus influenzae type b. Anti-PRP antibodies confer protection against invasive Hib disease.

Biological functions

Induction of immune response against Haemophilus influenzae type b (Hib)Generation of anti-PRP antibodies for protection from invasive Hib disease

Disease associations

Infection: Used to prevent invasive disease caused by Haemophilus influenzae type b, including meningitis, septicemia, and pneumonia

Safety considerations

Allergic reactions (to vaccine components)Local and systemic side effects typical of vaccines (injection site pain, fever, swelling)In rare cases, severe hypersensitivity reactionsNot for use in individuals with known allergy to any component

Interacting drugs

Hiberix

3 more in the full profile.

Biomarkers

Anti-PRP IgG antibody levels (e.g., 0.15 mcg/mL considered minimal protective level)

Beyond the preview

Go deeper on Haemophilus influenzae type b polyribosyl-ribitol-phosphate polysaccharide–tetanus toxoid conjugate (PRP-T).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haemophilus influenzae type b polyribosyl-ribitol-phosphate polysaccharide–tetanus toxoid conjugate (PRP-T).

Explore the full profile